Invasive Fungal Infections
The sponsor’s clinical research includes treatment areas for candidemia and invasive candidiasis, with attention to serious bloodstream and deep-seated fungal disease in adults.
- Fosmanogepix
- Systemic Candida infections
- Oral step-down antifungal therapy
These studies focus on difficult-to-treat fungal infections that require effective systemic antifungal options across hospital and specialist care settings.
Invasive Mold Disease
Another major area of interest is invasive mold infections, including disease caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, and Mucorales fungi.
- Multidrug-resistant molds
- Rare mold pathogens
- Severe pulmonary and disseminated fungal disease
The therapeutic focus extends to infections with limited treatment options, where novel antifungal approaches are needed for adults with complex fungal disease.
Severe Bacterial Pneumonia
The sponsor also supports research in community-acquired bacterial pneumonia, reflecting interest in serious respiratory infections that require inpatient management.
- Lower respiratory tract infection
- Acute bacterial pneumonia
- Hospital-treated respiratory infection
This area aligns with the clinical need for antibacterial therapies in adults with significant respiratory illness.
Gram-Negative Bacterial Infections
Clinical activity also covers severe infections caused by Gram-negative bacteria, a field associated with resistant and high-burden hospital infections.
- Antibacterial treatment
- Resistant Gram-negative pathogens
- Serious systemic infection
These studies support development in antibacterial therapy for infections that remain challenging in acute care settings.
